Synthèse et validation de modulateurs négatifs des canaux ioniques Orai1 pour la sensibilisation aux chimiothérapies du cancer de l'ovaire // Synthesis and validation of Orai1 modulators to enhance the sensitivity of ovarian cancer to chemotherapy
|
ABG-136937
ADUM-72458 |
Thesis topic | |
| 2026-03-20 | Public funding alone (i.e. government, region, European, international organization research grant) |
Université d'Orléans
ORLEANS - Centre Val de Loire - France
Synthèse et validation de modulateurs négatifs des canaux ioniques Orai1 pour la sensibilisation aux chimiothérapies du cancer de l'ovaire // Synthesis and validation of Orai1 modulators to enhance the sensitivity of ovarian cancer to chemotherapy
- Chemistry
Hétérocycles, Chimie médicinale, Chemical Biology, Oncologie, SAR, Canal ionique
Heteroycles, Medicinal Chemistry, Chemical Biology, Oncology, SAR, Ionic channel
Heteroycles, Medicinal Chemistry, Chemical Biology, Oncology, SAR, Ionic channel
Topic description
Depuis une vingtaine d'années, de nouvelles voies thérapeutiques ciblant l'expression et la fonction aberrante de canaux ioniques, ont été proposés du fait de leur impact tumoral (prolifération, migration et invasion) et la résistance aux traitements. Nos équipes (ICOA et N2COx) ont développé des séries chimiques sélectives inhibant significativement l'entrée de calcium dépendante de la vidange du réticulum sarcoplasmique (SOCE) afin de stopper la migration des cellules cancéreuses et de sensibiliser les cellules cancéreuses à la chimiothérapie conventionnelle. Dans ce contexte, nous proposons de développer une stratégie thérapeutique via la synthèse et l'optimisation de modulateurs négatifs puissants et spécifiques inédits du canal Orai1 (ICOA) et dans un objectif diagnostique, nous synthétiserons, pour les molécules les plus pertinentes, des sondes de « chemical biology » qui permettront la détection rapide et simple des canaux Orai1 au niveau cellulaire et tissulaire.
Ce projet est soutenu par la Ligue contre le Cancer.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Over the past twenty years or so, new therapeutic approaches targeting the abnormal expression and function of ion channels have been proposed due to their impact on tumour behaviour (proliferation, migration and invasion) and resistance to treatment. Our teams (ICOA and N2COx) have developed selective chemical series that significantly inhibit calcium entry dependent on sarcoplasmic reticulum (SOCE) depolarisation in order to halt the migration of cancer cells and sensitise them to conventional chemotherapy. In this context, we propose to develop a therapeutic strategy through the synthesis and optimisation of novel, potent and specific negative modulators of the Orai1 channel (ICOA) and, for diagnostic purposes, we will synthesise ‘chemical biology' probes for the most relevant molecules, which will enable the rapid and simple detection of Orai1 channels at the cellular and tissue levels.
This project is supported by the League Against Cancer.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Début de la thèse : 01/10/2026
Ce projet est soutenu par la Ligue contre le Cancer.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Over the past twenty years or so, new therapeutic approaches targeting the abnormal expression and function of ion channels have been proposed due to their impact on tumour behaviour (proliferation, migration and invasion) and resistance to treatment. Our teams (ICOA and N2COx) have developed selective chemical series that significantly inhibit calcium entry dependent on sarcoplasmic reticulum (SOCE) depolarisation in order to halt the migration of cancer cells and sensitise them to conventional chemotherapy. In this context, we propose to develop a therapeutic strategy through the synthesis and optimisation of novel, potent and specific negative modulators of the Orai1 channel (ICOA) and, for diagnostic purposes, we will synthesise ‘chemical biology' probes for the most relevant molecules, which will enable the rapid and simple detection of Orai1 channels at the cellular and tissue levels.
This project is supported by the League Against Cancer.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Début de la thèse : 01/10/2026
Funding category
Public funding alone (i.e. government, region, European, international organization research grant)
Funding further details
Concours pour un contrat doctoral
Presentation of host institution and host laboratory
Université d'Orléans
Institution awarding doctoral degree
Université d'Orléans
Graduate school
549 Santé, Sciences Biologiques et Chimie du Vivant - SSBCV
Candidate's profile
Le (la) candidat(e) devra être titulaire d'un M2, avoir suivi une formation incluant de la chimie organique et avoir un intérêt pour la chimie thérapeutique.
Un stage académique ou industriel réussi en synthèse organique est requis.
Merci de fournir avant le 15/04/2026: CV+ une lettre de motivation+ notes (rangs) de M1 et M2. Les entretiens s'effectueront au fil de l'eau.
Une lettre de recommandation de l'encadrant de stage de fin d'étude est souhaitable.
The candidate must hold a Master's degree (M2), have studied organic chemistry as part of their course, and have an interest in medicinal chemistry. A successful academic or industrial placement in organic synthesis is required. Please submit the following by 17 April 2026: CV, a covering letter and your Master's (M1 and M2) grades (rankings). Interviews will be held on a rolling basis. A letter of recommendation from your final-year placement supervisor is desirable.
The candidate must hold a Master's degree (M2), have studied organic chemistry as part of their course, and have an interest in medicinal chemistry. A successful academic or industrial placement in organic synthesis is required. Please submit the following by 17 April 2026: CV, a covering letter and your Master's (M1 and M2) grades (rankings). Interviews will be held on a rolling basis. A letter of recommendation from your final-year placement supervisor is desirable.
2026-04-17
Apply
Close
Vous avez déjà un compte ?
Nouvel utilisateur ?
Get ABG’s monthly newsletters including news, job offers, grants & fellowships and a selection of relevant events…
Discover our members
Groupe AFNOR - Association française de normalisation
Nantes Université
ANRT
ONERA - The French Aerospace Lab
Tecknowmetrix
SUEZ
Aérocentre, Pôle d'excellence régional
Généthon
Servier
ADEME
Laboratoire National de Métrologie et d'Essais - LNE
Ifremer
Nokia Bell Labs France
Institut Sup'biotech de Paris
TotalEnergies
Medicen Paris Region
ASNR - Autorité de sûreté nucléaire et de radioprotection - Siège

